(161 days)
Not Found
No
The device description and performance studies focus on the physical properties, antimicrobial agent, and clinical tolerability of a wound dressing. There is no mention of AI or ML in the text.
No.
The device is a wound dressing that absorbs exudate and covers and protects catheter sites; it does not claim to treat any medical condition.
No.
The device is a dressing intended to protect catheter sites and absorb exudate, not to diagnose a medical condition.
No
The device description clearly describes a physical wound dressing impregnated with an antimicrobial agent, not a software application.
Based on the provided text, the ChloraShield™ Antimicrobial Dressing is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is as a wound dressing to absorb exudate and cover/protect catheter sites. This is a topical application for wound management and protection, not for testing samples outside the body.
- Device Description: The description focuses on the physical properties of the dressing (transparent, conformable, oval shaped) and the presence of an antimicrobial agent to protect the dressing itself and the site. It does not describe any components or processes for analyzing biological samples.
- Lack of IVD Characteristics: IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening. The ChloraShield™ dressing does not perform any such analysis.
The device is clearly intended for direct application to the body for wound care and site protection.
N/A
Intended Use / Indications for Use
The ChloraShield™ Antimicrobial Dressing is intended for use as a wound dressing to absorb exudate and to cover and protect catheter sites. Common applications include IV catheters, other intravascular catheters and percutaneous devices.
Product codes (comma separated list FDA assigned to the subject device)
FRO
Device Description
The ChloraShield™ Antimicrobial Dressing is intended to fill the need for a transparent primary catheter dressing that can be applied easily while surrounding the wound site.
The dressing is an oval shaped dressing intended to cover and protect a catheter site and absorb exudates.
The dressing is transparent and conformable allowing for easy visual and manual inspection of IV sites.
The dressing is impregnated with Chlorhexidine Gluconate (CHG), a persistent, broad spectrum antimicrobial and antifungal activity against a wide range of gram positive and gram negative organisms. The antimicrobial agent protects the dressing from bacterial penetration and colonization. The patch complements other infection control measures by providing continued IV site protection while also allowing for good site visualization and inspection.
ChloraShield has not been clinically tested for its ability to reduce local infections, catheter-related blood stream infections (CRBSI) or skin colonization of microorganisms commonly related to CRBSI.
The product is sold in a sterile condition, opened in the operating field and then applied to the catheter site.
Like the predicate devices, the ChloraShield ™ Dressing is easy to apply and easy to remove.
The product offering includes: The product number is: # 410100 standard package - one dressing or patch per sterile package.
The proposed device is similar to the predicate devices and uses biocompatible materials that are merged into a dressing that is breathable, transparent and easy to apply and remove. The device consists of a polypropylene mesh that holds or has been imbibed with a proprietary hydrogel that contains the active ingredient. The product is supplied in a sterile condition with one product per foil laminate pouch.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Catheter sites, IV sites, skin sites
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A clinical study was conducted which compared the tolerability (frequency and severity of skin reactions) at skin sites across a wear period of seven days. Forty-five subjects participated in the study (15 subjects per treatment group).
The safety assessment in the clinical study was designed to evaluate if an exaggerated use model would cause irritation or adverse events in normal healthy volunteers when receiving multiple test article applications over a seven-day duration of exposure. The study design employed an initial high dose exposure, (7 times the exposure of the intended clinical use), on Day 1 and daily descending exposure of one patch each day over the 7 day wear period.
The tolerability of the proposed device was found to be equivalent to the predicate devices and additional detail is provided in the submission. the use of placebos and, comparisons against the predicate devices including tests on mice, rabbits and guinea pigs. Standardized test methods from ASTM and ISO were used in this testing and are described in the submission.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
N/A
0
Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services (HHS). The logo consists of a stylized graphic of an eagle or bird in flight, composed of three curved lines. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the graphic. The text is in all capital letters and is evenly spaced around the circle.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
CareFusion 213 LLC % Arlen Johnson Sr. Regulatory Affairs Specialist 1550 Northwestern Drive El Paso, Texas 79912
MAR 3 0 2011
Re: K103106
Trade/Device Name: ChloraShield™ Antimicrobial Dressing Regulatory Class: Unclassified Product Code: FRO Dated: March 17, 2011 Received: March 21, 2011
Dear Arlen Johnson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21
1
Page 2 – Arlen Johnson
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
A. B. R. h
Mark N. Melkerson Director Division of Surgical, Orthopedic And Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
INDICATIONS FOR USE
510(k) Number (if known): K 103106
Device Name: ChloraShield™ Antimicrobial Dressing
Indications for use:
The ChloraShield™ Antimicrobial Dressing is intended for use as a wound dressing to absorb exudate and to cover and protect catheter sites. Common applications include IV catheters, other intravascular catheters and percutaneous devices.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
AND/OR
Prescription Use
X
Over-The-Counter Use
Daniel Kramer for MXM
(Division Sign Off)
(Division Sign-C Division of Surgical, Orthopedic. and Restorative Devices
510(k) Number K103106
3
Image /page/3/Picture/1 description: The image shows the CareFusion logo. The logo consists of an orange circle with a white shield inside, and the text "CareFusion" in gray. The shield has a small orange section in the upper left corner. The text is to the right of the circle.
In accordance with 21 CFR 807.92 the following summary of information is provided:
| Date: | March 18, 2010 |
|---|---|
| Submitter: | CareFusion 213 LLC |
| 1550 Northwestern Drive | |
| El Paso, TX 79912 | |
| Primary Contact Person: | Arlen Johnson |
| Sr. Regulatory Affairs Specialist | |
| Phone: (913) 345-3570 | |
| Fax: (614)757-6080 | |
| arlen.johnson@carefusion.com | |
| Alternate Contact: | Frank Pokrop |
| 6550 Lusk Blvd. | |
| San Diego, CA 92121 | |
| 858-617-4364 | |
| frank.pokrop@carefusion.com | |
| Device Trade Name: | ChloraShield™ Antimicrobial Dressing |
| Common Trade Name: | Antimicrobial Dressing |
| Classification: | Unclassified |
| Panel: | General, Restorative, and Neurological Devices |
| Product Code (Primary): | FRO |
| Predicate Devices: | Two predicate devices are identified in this submission |
| 510(k) # | Date of Clearance | Company | |
|---|---|---|---|
| 1 | K003229 | 10-26-2001 | Integra |
| Lifesciences | |||
| 2 | K063458 | 4-5-2007 | 3M |
The ChloraShield™ Antimicrobial Dressing is intended to Device Description: fill the need for a transparent primary catheter dressing that can be applied easily while surrounding the wound site.
The dressing is an oval shaped dressing intended to cover and protect a catheter site and absorb exudates.
4
Image /page/4/Picture/1 description: The image contains the logo for CareFusion. The logo consists of an orange circle with a white shield inside. The shield has a small orange triangle in the upper right corner. To the right of the circle is the text "CareFusion" in a dark gray sans-serif font.
In accordance with 21 CFR 807.92 the following summary of information is provided:
| Device Description: | The dressing is transparent and conformable allowing for easy visual and manual inspection of IV sites.
The dressing is impregnated with Chlorhexidine Gluconate (CHG), a persistent, broad spectrum antimicrobial and antifungal activity against a wide range of gram positive and gram negative organisms. The antimicrobial agent protects the dressing from bacterial penetration and colonization. The patch complements other infection control measures by providing continued IV site protection while also allowing for good site visualization and inspection.
ChloraShield has not been clinically tested for its ability to reduce local infections, catheter-related blood stream infections (CRBSI) or skin colonization of microorganisms commonly related to CRBSI.
The product is sold in a sterile condition, opened in the operating field and then applied to the catheter site.
Like the predicate devices, the ChloraShield TM Dressing is easy to apply and easy to remove.
The product offering includes: The product number is: # 410100 standard package - one dressing or patch per sterile package. |
|-------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use: | The ChloraShield TM Antimicrobial Dressing is intended for use as a wound dressing to absorb exudate and to cover and protect catheter sites. Common applications include IV catheters, other intravascular catheters and percutaneous devices. |
| Technology: | The proposed device is similar to the predicate devices and uses biocompatible materials that are merged into a dressing that is breathable, transparent and easy to apply and remove. The device consists of a polypropylene mesh that holds or has been imbibed with a proprietary hydrogel that contains the active ingredient. The product is supplied in a sterile condition with one product per foil laminate pouch. |
| Determination of Substantial Equivalence: | Summary of Non-Clinical Tests: A variety of non-clinical tests were conducted to show the safety and effectiveness of the proposed device including |
5
Image /page/5/Picture/1 description: The image contains the logo for CareFusion. The logo consists of an orange circle with a white shield inside. The shield has a small orange corner at the top right. To the right of the circle is the text "CareFusion" in a gray sans-serif font.
| In accordance with 21 CFR 807.92 the following summary of information is provided: | |
|---|---|
| Determination of Substantial | |
| Equivalence: | Summary of Clinical Tests: |
| A clinical study was conducted which compared the | |
| tolerability (frequency and severity of skin reactions) at | |
| skin sites across a wear period of seven days. Forty-five | |
| subjects participated in the study (15 subjects per | |
| treatment group). |
The safety assessment in the clinical study was designed
to evaluate if an exaggerated use model would cause
irritation or adverse events in normal healthy volunteers
when receiving multiple test article applications over a
seven-day duration of exposure. The study design
employed an initial high dose exposure, (7 times the
exposure of the intended clinical use), on Day 1 and daily
descending exposure of one patch each day over the 7
day wear period.
The tolerability of the proposed device was found to be
equivalent to the predicate devices and additional detail is
provided in the submission. the use of placebos and, comparisons against the
predicate devices including tests on mice, rabbits and
guinea pigs. Standardized test methods from ASTM and
ISO were used in this testing and are described in the
submission. |
| Standards Used in the
Testing and Development of
this Product: | ISO 11607-2:2006. Packaging for terminally
sterilized medical devices -- Part 2: Validation
requirements for forming, sealing and assembly
processes ISO 11135-1:2007. Sterilization of health care
products -- Ethylene oxide -- Part 1: Requirements
for development, validation and routine control of
a sterilization process for medical devices ISO 10993-7:1995 (R) 2001. Biological evaluation
of medical devices -- Part 7: Ethylene oxide
sterilization residuals ASTM D4169 - 09 Standard Practice for Performance
Testing of Shipping Containers and Systems |
6
Image /page/6/Picture/0 description: The image shows the text "ChloraShield™ Antimicrobial Dressing". The text is in a sans-serif font and is black. The word "ChloraShield" is followed by the trademark symbol. The text is centered in the image.
Image /page/6/Picture/1 description: The image contains the logo for CareFusion. The logo consists of an orange circle with a white shield inside. The shield has an orange accent on the top left corner. To the right of the circle is the text "CareFusion" in a gray, sans-serif font.
In accordance with 21 CFR 807.92 the following summary of information is provided:
-
. ASTM D4728 - 06 Standard Test Method for Random Vibration Testing of Shipping Containers
Standards Used in the Testing and Development of this Product: CLSI (Clinical and Laboratory Standards Institute): -
. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard - Ninth Edition; M2-A9: Sept. 2006
-
. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Tenth Edition; M2-A10: Jan 2009
-
The applicant considers the ChloraShield™ Antimicrobial Conclusion: Dressing to be safe and effective, and its performance is substantially equivalent to the two predicate devices.